Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Study of Efficacy and Safety of Interferon Gamma Combined With Camrelizumab for Neoadjuvant Therapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.

Inclusion Criteria:

1. Aged >= 18 years;
2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
4. Expected overall survival > 6 months;
5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function.

Exclusion Criteria:

1. Active autoimmune disease;
2. Requirement for systemic immunosuppressive therapy;
3. Hypersensitivity to any study drug;
4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection;
5. Pregnant or lactating female.